Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system-Reference-Cited by-同舟云学术

Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system

Published:2021-06-04 Issue:7 Volume:5 Page:778-784
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Taher Mohamed Kadry¹²³^ORCID,Alami Abdallah³,Gravel Christopher A.¹²⁴^ORCID,Tsui Derek³,Bjerre Lise M.²⁵⁶,Momoli Franco²³⁷,Mattison Donald R.¹³,Krewski Daniel¹²³

Affiliation:

1. McLaughlin Centre for Population Health Risk Assessment, Faculty of Medicine University of Ottawa Ottawa ON Canada

2. School of Epidemiology and Public Health University of Ottawa Ottawa ON Canada

3. Risk Sciences International Ottawa ON Canada

4. Department of Epidemiology, Biostatistics and Occupational Health McGill University Montreal QC Canada

5. Department of Family Medicine University of Ottawa Ottawa ON Canada

6. C.T. Lamont Primary Health Care Research Centre Bruyère Research Institute Ottawa ON Canada

7. Children's Hospital of Eastern Ontario Research Institute Ottawa ON Canada

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12585

Reference52 articles.

1. Safety Profile of the Fluoroquinolones

2. The Newer Fluoroquinolones

3. Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections

4. Safety of fluoroquinolones in paediatrics

5. Risks associated with the therapeutic use of fluoroquinolones

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS;Frontiers in Pharmacology;2024-09-03

2. Safety of fluoroquinolones;Revista Española de Quimioterapia;2023-12-22

3. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?;Pharmaceutics;2023-03-01

4. Which patient factors increase the risk of fluoroquinolone-associated reactions?;JAAPA;2023-02